Immunome Property Plant Equipment from 2010 to 2024

IMNM Stock  USD 9.82  0.40  4.25%   
Immunome Property Plant Equipment yearly trend continues to be very stable with very little volatility. Property Plant Equipment is likely to grow to about 1.1 M this year. During the period from 2010 to 2024, Immunome Property Plant Equipment quarterly data regression pattern had sample variance of 331.1 B and median of  2,082,000. View All Fundamentals
 
Property Plant Equipment  
First Reported
2010-12-31
Previous Quarter
612.9 K
Current Value
1.1 M
Quarterly Volatility
575.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunome financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunome's main balance sheet or income statement drivers, such as Net Interest Income of 2.9 M, Interest Income of 2.9 M or Depreciation And Amortization of 736.1 K, as well as many indicators such as Price To Sales Ratio of 12.12, Dividend Yield of 0.0 or PTB Ratio of 1.86. Immunome financial statements analysis is a perfect complement when working with Immunome Valuation or Volatility modules.
  
Check out the analysis of Immunome Correlation against competitors.
To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.

Latest Immunome's Property Plant Equipment Growth Pattern

Below is the plot of the Property Plant Equipment of Immunome over the last few years. It is Immunome's Property Plant Equipment historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunome's overall financial position and show how it may be relating to other accounts over time.
Property Plant Equipment10 Years Trend
Slightly volatile
   Property Plant Equipment   
       Timeline  

Immunome Property Plant Equipment Regression Statistics

Arithmetic Mean1,680,916
Geometric Mean1,554,533
Coefficient Of Variation34.23
Mean Deviation483,845
Median2,082,000
Standard Deviation575,425
Sample Variance331.1B
Range1.5M
R-Value(0.83)
Mean Square Error108.5B
R-Squared0.70
Significance0.0001
Slope(107,313)
Total Sum of Squares4.6T

Immunome Property Plant Equipment History

20241.1 M
2023612.9 K
2022681 K
2021855 K
20201.5 M
20191.7 M

About Immunome Financial Statements

Immunome investors utilize fundamental indicators, such as Property Plant Equipment, to predict how Immunome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Property Plant Equipment612.9 K1.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports:
Check out the analysis of Immunome Correlation against competitors.
To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.94)
Revenue Per Share
0.189
Quarterly Revenue Growth
(0.18)
Return On Assets
(0.40)
Return On Equity
(2.76)
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.